Patent 9186392 was granted and assigned to Boehringer Ingelheim on November, 2015 by the United States Patent and Trademark Office.
The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.